News 10 Jul 2026 Jae-Hyung Jang, CTO of GluGene Therapeutics, Named Among Top 30 Health & Medical R&D Achievements by Ministry of Health and Welfare Professor Jae-Hyung Jang of the Department of Chemical and Biomolecular Engineering at Yonsei University has been selected for the "Top… GluGene
News 08 Jul 2026 Global Scholars Join GluGene Therapeutics’ Newly Activated Scientific Advisory Board GluGene Therapeutics (CEO Moonsoo Lee) announced on the 1st that it has established a Scientific Advisory Board (SAB). GluGene Therapeutics… GluGene
News 29 Jun 2026 GluGene Therapeutics Selected for ‘TRL Jump-up’ Program… Set to Expand Pipeline GluGene Therapeutics (CEO Moon-Soo Lee), a gene therapy company specializing in the development of next-generation precision-guided AAV (Adeno-Associated Virus) vectors,… GluGene
News 15 May 2026 GlueGene Therapeutics Unveils AAV Vector Primate Targeting Results at ASGCT 2026 GGT-100 Vector achieves precision targeting of pulmonary artery smooth muscle cells in non-human primates GlueGene Therapeutics (CEO Moon-soo Lee), a… GluGene
News 30 Apr 2026 [2026 First Half Innovative Patent Technology Awards] Developing Gene Therapies Using AI Glugene Therapeutics (CEO Moon-soo Lee) is expanding its business based on its precision gene delivery (AAV) development technology. The company… GluGene
News 25 Mar 2026 GluGene Therapeutics: Democratizing Gene Therapy with Precision-Guided AAV Technology "While the majority of FDA-approved gene therapies utilize AAV (Adeno-Associated Virus), these vectors often migrate to non-target tissues, necessitating high-dose… GluGene
News 10 Mar 2026 Donor Interview: Professor Jae-Hyung Jang, Department of Chemical and Biomolecular Engineering (CTO of GluGene Therapeutics) 1. Could you please provide a brief self-introduction for the Yonseians and subscribers reading this article? I am Jae-Hyung Jang,… GluGene
News 24 Feb 2026 Rznomics and GluGene Therapeutics Partner to Develop Next-Generation RNA Gene Therapies Rznomics, a leader in RNA-based gene therapeutics, and GluGene Therapeutics, an innovator in Adeno-Associated Virus (AAV) vector engineering, have entered… GluGene
News 13 Oct 2025 GluGene Therapeutics Showcases a Data-driven AAV Engineering Platform for Next-Generation In Vivo Gene Therapy at ESGCT GluGene Therapeutics announced the presentation of four independent studies at the Annual Congress of the European Society of Gene &… GluGene
News 21 May 2025 GluGene Therapeutics Secures Initial Financial Investor Participation in Series A Financing Round GluGene Therapeutics, a biotechnology company developing advanced adeno-associated virus (AAV) platform technologies for next-generation gene therapies, announced that participation by… GluGene
